Dave, I got the sense that the company is trying t

Dave, I got the sense that the company is trying to make diligent, calculated moves with MANF, especially centered on "druggable" indications like RP. Gerald specifically brought up eye indications due to the ease of dosing. His mention of pre-IND meetings with the FDA was very encouraging (and I've learned tonight that I wasn't the only one in there today who heard him say they would be starting the process in a couple of days).

That being said, it's hard for me to make a prediction on timeframe for the first MANF orphan. Everyone on the company side of the table seemed to be very in touch with the realities of dealing with the FDA, and that things don't always go according to schedule or as fast as us shareholders would like. one very interesting tidbit that I didn't mention in my initial report was that a question was asked regarding government relations (I believe the question was initially directed at Robert Harris). Mr. Harris quickly turned to Gerald and said that Gerald would be better suited to answer since he had been working a lot in that area (federal government relations... presumably including FDA).

There was very little talk, if any, of an uplisting in the meeting today. I personally welcomed that, since it allowed for more in-depth discussion of the science and also for the couple of tantalizing near-spills of data from John and lively commentary from Rubinfeld. The feeling I got was that everyone in the room knows we're headed for an uplist (the signs are all there) but they are being calm about it and want to let it happen at the best possible time.